A phase 1b study of TLC-6740 in patients with obesity and type 2 diabetes
Latest Information Update: 11 Sep 2024
At a glance
- Drugs TLC 6740 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- 11 Sep 2024 New trial record
- 06 Sep 2024 According to an OrsoBio media release, trial will initiate in coming months.